Ofloxacin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ofloxacin: From Bacterial Infections to Monoclonal Gammopathy
One-Sentence Summary
Ofloxacin is a fluoroquinolone antibiotic used broadly for bacterial infections, though it is not currently marketed in Taiwan. The TxGNN model predicts a repurposing opportunity in Monoclonal Gammopathy — specifically as prophylactic antibiotic therapy to prevent infection-related mortality in newly diagnosed multiple myeloma — supported by 19 publications, including two completed Phase 3 RCTs, though the RCT evidence is for levofloxacin (a stereoisomer of ofloxacin) rather than ofloxacin itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bacterial infections (fluoroquinolone antibiotic class); no Taiwan license/indication text on file |
| Predicted New Indication | Monoclonal Gammopathy (infection prophylaxis in newly diagnosed multiple myeloma) |
| TxGNN Prediction Score | 99.82% |
| Evidence Level | L2 |
| US Market Status | 未上市 (Not Marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, ofloxacin is a second-generation fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication in susceptible gram-negative and gram-positive organisms. Its antimicrobial spectrum is essentially the same as that of levofloxacin, its more widely studied levo-isomer.
Multiple myeloma (the malignancy underlying monoclonal gammopathy) causes profound humoral immunodeficiency, and roughly a quarter of newly diagnosed patients experience a serious infection within three months of diagnosis. This is not a case of ofloxacin treating the malignancy itself — rather, the predicted benefit is antibacterial prophylaxis during the high-risk induction/transplant period, where fluoroquinolones reduce febrile neutropenia and bloodstream infection episodes.
The key caveat is that the strongest evidence (the TEAMM Phase 3 RCT) was conducted with levofloxacin, not ofloxacin. Since both drugs share the same core fluoroquinolone mechanism and overlapping spectrum, a class-effect extrapolation is mechanistically plausible, but it has not been directly validated for ofloxacin in this population.
Clinical Trial Evidence
Currently no related clinical trials registered.
(Supporting RCT evidence exists but is captured under Literature Evidence below — the pivotal TEAMM trial (PMID 31668592 / 31690402) was a registered multicentre Phase 3 RCT, but it was ingested via PubMed rather than as a clinical trial registry record in this evidence pack.)
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31668592 | 2019 | RCT | The Lancet Oncology | TEAMM trial: levofloxacin prophylaxis in newly diagnosed myeloma reduced serious infections vs. placebo in a multicentre, double-blind, Phase 3 RCT |
| 31690402 | 2019 | RCT | Health Technology Assessment | Full TEAMM RCT report: prophylactic levofloxacin reduced febrile episodes/death in first 12 weeks post-diagnosis without significant increase in C. difficile infection |
| 37573150 | 2023 | Cohort | Transplant Infectious Disease | Infectious complications after autologous HCT in myeloma patients; evaluated outcomes with/without levofloxacin prophylaxis |
| 32019731 | 2020 | Cohort | Clin Lymphoma Myeloma Leuk | Real-world Asian cohort: bacterial infection rates during bortezomib-based induction without routine fluoroquinolone prophylaxis |
| 26150022 | 2015 | Cohort | Biol Blood Marrow Transplant | Prophylactic levofloxacin reduced bloodstream infection and febrile neutropenia rates in autologous HSCT for myeloma |
| 25212681 | 2014 | Cohort | Int J Hematol | Levofloxacin prophylaxis reduced severe infections in myeloma patients on bortezomib-based regimens |
| 29080369 | 2018 | Cohort | Clinical Transplantation | Retrospective comparison of ciprofloxacin vs. levofloxacin prophylaxis in autologous HSCT for myeloma — similar breakthrough infection rates |
| 32304873 | 2020 | Review | Biol Blood Marrow Transplant | Reviews controversy and evidence base for fluoroquinolone prophylaxis in autologous stem cell transplantation |
| 32172361 | 2020 | Review | Curr Hematol Malig Rep | Supportive care review in multiple myeloma, including infection prevention strategies |
| 15791505 | 2005 | Cohort | Clinical Infectious Diseases | Fluoroquinolone prophylaxis associated with reduced infection-related mortality in neutropenic hematologic malignancy patients |
US Market Information
No Taiwan or US license records are available for ofloxacin in this evidence pack (market_status: 未上市 / Not Marketed; total_licenses: 0).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The TEAMM Phase 3 RCT and multiple supporting cohort studies provide solid L2-level evidence that fluoroquinolone prophylaxis reduces infection-related mortality in newly diagnosed multiple myeloma. However, this evidence was generated with levofloxacin, not ofloxacin directly, so the class-effect assumption needs explicit validation before clinical application.
To proceed, the following is needed:
- Resolve DG001 (Blocking): obtain TFDA/international package insert warnings and contraindications before any safety sign-off
- Resolve DG002 (High): confirm ofloxacin’s detailed MOA and pharmacokinetic comparability to levofloxacin to support class-effect extrapolation
- Direct evidence (even pharmacokinetic/PD bridging data) on ofloxacin specifically in neutropenic/myeloma populations, since current RCT support is for its levo-isomer
- A defined monitoring and antimicrobial stewardship plan given fluoroquinolone-class risks (e.g., C. difficile infection, resistance selection) noted in the supporting literature
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.